Cooperative Agreement 7200AA21CA00021

The Defense Health Agency awarded a $215,429 Project Grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis. This two-year grant, running from July 2024 to July 2026, supports TB Alliance's research and development efforts to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The funding falls under the Military...

This $7,352,643 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports efforts by The Global Alliance For TB Drug Development Inc. (TB Alliance) to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The grant, awarded on September 30, 2024 with a completion date of September 29, 2028, will fund TB Alliance's research on innovative, host-directed approaches to target...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405.00 to Colorado State University and its subrecipient, the University of Tennessee Health Science Center, to develop new drug regimens for treating tuberculosis (TB), including both drug-sensitive and multidrug-resistant strains. The key objectives are to: 1) manufacture and characterize inhalable dry...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $766,877 randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) for linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The primary objective is to determine if TDM can prevent premature discontinuation of linezolid, a critical drug for treating RR-TB. The...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing novel antituberculosis (TB) drugs that can address emerging drug resistance. The $302,421 award to Progenra Inc., a biotechnology firm in Malvern, Pennsylvania, will fund research to evaluate parkin activators as potential treatments for both drug-sensitive and drug-resistant TB. The project aims to...

This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $265,650 to HMH Hospitals Corporation (Hackensack University Medical Center) to conduct research on novel rifabutin analogs as a strategy to overcome drug-resistant tuberculosis (MDR/RR-TB). The primary goals are to: (1) establish the structure-activity relationship and mechanism of action of MDR-TB active rifabutin...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $817,252 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center (VUMC) to conduct a study entitled "Investigating Multiple PK and PD Relationships for TB-HIV (IMPPROVE TB-HIV)". This 1-year project aims to leverage VUMC's Tuberculosis Sentinel Research Network to perform pharmacokinetic-pharmacodynamic (PK-PD) analyses on first-line...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to the University of California, Los Angeles (UCLA) to design and develop a rapid phenotypic drug susceptibility test, termed TRE-DST, for tuberculosis (TB). The TRE-DST system utilizes novel fluorescent trehalose probes to specifically detect live Mycobacterium tuberculosis (MTB) and determine drug...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Trustees of Columbia University in the City of New York, totaling $166,541. The grant, titled "RIFAPENTINE IN HIGH DOSES IN PREGNANCY WITH TB (RADIANT-MOMS) STUDY", will be used to conduct research on optimizing tuberculosis (TB) treatment for pregnant and breastfeeding people. The key objectives of the project are to:...